Acumen Pharmaceuticals (ABOS) Change in Accured Expenses (2020 - 2026)
Acumen Pharmaceuticals recorded quarterly Change in Accured Expenses of -$5.0 million in Q1 2026, down 325.64% quarter-over-quarter from $2.2 million in Q4 2025, and down 8505.0% year-over-year from $60000.0 in Q1 2025.
Acumen Pharmaceuticals' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$5.0 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 8505.0% year-over-year to -$5.0 million; the TTM figure through Mar 2026 stood at -$1.8 million (down 149.71% YoY), while the FY2025 annual figure was $3.3 million, up 10215.62% from the prior year.
- Change in Accured Expenses came in at -$5.0 million for Q1 2026 at Acumen Pharmaceuticals, down from $2.2 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $4.9 million in Q2 2025 to a low of -$5.0 million in Q1 2026.
- A 5-year average of $35705.9 and a median of $370000.0 in 2022 frame the typical range for Change in Accured Expenses.
- Across the five-year window, Change in Accured Expenses surged 6266.67% in 2022 and slumped 8505.0% in 2026, its largest moves.
- Acumen Pharmaceuticals' Change in Accured Expenses stood at $500000.0 in 2022, then jumped by 512.2% to $3.1 million in 2023, then sank by 50.18% to $1.5 million in 2024, then jumped by 46.56% to $2.2 million in 2025, then sank by 325.64% to -$5.0 million in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$5.0 million, $2.2 million, and -$3.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Acumen Pharmaceuticals | 164.37 Mn | 35.97 Mn | - | -5.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.04 Mn |
| Mar 31, 2026 | -5.04 Mn |
| Dec 31, 2025 | 2.24 Mn |
| Dec 31, 2025 | 2.24 Mn |
| Sep 30, 2025 | -3.90 Mn |
| Sep 30, 2025 | -3.90 Mn |
| Jun 30, 2025 | 4.90 Mn |
| Jun 30, 2025 | 4.90 Mn |
| Mar 31, 2025 | 60,000.00 |
| Mar 31, 2025 | 60,000.00 |
| Dec 31, 2024 | 1.53 Mn |
| Dec 31, 2024 | 1.53 Mn |
| Sep 30, 2024 | 892,000.00 |
| Sep 30, 2024 | 892,000.00 |
| Jun 30, 2024 | 1.15 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Mar 31, 2024 | -3.53 Mn |
| Mar 31, 2024 | -3.53 Mn |
| Dec 31, 2023 | 3.06 Mn |
| Dec 31, 2023 | 3.06 Mn |
| Sep 30, 2023 | 831,000.00 |
| Sep 30, 2023 | 831,000.00 |
| Jun 30, 2023 | -410,000.00 |
| Jun 30, 2023 | -410,000.00 |
| Mar 31, 2023 | -603,000.00 |
| Mar 31, 2023 | -603,000.00 |
| Dec 31, 2022 | 500,000.00 |
| Dec 31, 2022 | 500,000.00 |
| Sep 30, 2022 | 370,000.00 |
| Sep 30, 2022 | 370,000.00 |
| Jun 30, 2022 | 330,000.00 |
| Jun 30, 2022 | 330,000.00 |
| Mar 31, 2022 | -1.76 Mn |
| Mar 31, 2022 | -1.76 Mn |
| Dec 31, 2021 | 2.80 Mn |
| Dec 31, 2021 | 2.80 Mn |
| Sep 30, 2021 | -6,000.00 |
| Sep 30, 2021 | -6,000.00 |
| Jun 30, 2021 | -263,000.00 |
| Jun 30, 2021 | -263,000.00 |
| Mar 31, 2021 | 954,000.00 |
| Mar 31, 2021 | 954,000.00 |
| Dec 31, 2020 | -853,000.00 |
| Dec 31, 2020 | -853,000.00 |
| Sep 30, 2020 | 587,000.00 |
| Sep 30, 2020 | 587,000.00 |